JP2013514381A5 - - Google Patents

Download PDF

Info

Publication number
JP2013514381A5
JP2013514381A5 JP2012544796A JP2012544796A JP2013514381A5 JP 2013514381 A5 JP2013514381 A5 JP 2013514381A5 JP 2012544796 A JP2012544796 A JP 2012544796A JP 2012544796 A JP2012544796 A JP 2012544796A JP 2013514381 A5 JP2013514381 A5 JP 2013514381A5
Authority
JP
Japan
Prior art keywords
patent application
filed
application ser
february
entirety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012544796A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013514381A (ja
JP5898627B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/060575 external-priority patent/WO2011084521A2/en
Publication of JP2013514381A publication Critical patent/JP2013514381A/ja
Publication of JP2013514381A5 publication Critical patent/JP2013514381A5/ja
Application granted granted Critical
Publication of JP5898627B2 publication Critical patent/JP5898627B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012544796A 2009-12-15 2010-12-15 エポチロンを含む治療用ポリマーナノ粒子ならびにそれを製造および使用する方法 Expired - Fee Related JP5898627B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US28655909P 2009-12-15 2009-12-15
US61/286,550 2009-12-15
US30672910P 2010-02-22 2010-02-22
US61/306,729 2010-02-22
US40577810P 2010-10-22 2010-10-22
US61/405,778 2010-10-22
PCT/US2010/060575 WO2011084521A2 (en) 2009-12-15 2010-12-15 Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same

Publications (3)

Publication Number Publication Date
JP2013514381A JP2013514381A (ja) 2013-04-25
JP2013514381A5 true JP2013514381A5 (enExample) 2013-12-26
JP5898627B2 JP5898627B2 (ja) 2016-04-06

Family

ID=50397493

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012544796A Expired - Fee Related JP5898627B2 (ja) 2009-12-15 2010-12-15 エポチロンを含む治療用ポリマーナノ粒子ならびにそれを製造および使用する方法

Country Status (5)

Country Link
US (2) US20150110837A9 (enExample)
EP (1) EP2512459A4 (enExample)
JP (1) JP5898627B2 (enExample)
EA (1) EA201290498A1 (enExample)
WO (1) WO2011084521A2 (enExample)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
EA020753B1 (ru) 2008-06-16 2015-01-30 Бинд Терапьютикс, Инк. Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение
ES2765240T3 (es) 2008-06-16 2020-06-08 Pfizer Nanopartículas poliméricas cargadas de fármaco y procedimientos de fabricación y uso de las mismas
WO2010068866A2 (en) 2008-12-12 2010-06-17 Bind Biosciences Therapeutic particles suitable for parenteral administration and methods of making and using same
ES2776126T3 (es) * 2008-12-15 2020-07-29 Pfizer Nanopartículas de circulación prolongada para la liberación sostenida de agentes terapéuticos
WO2011072218A2 (en) 2009-12-11 2011-06-16 Bind Biosciences Stable formulations for lyophilizing therapeutic particles
WO2011084513A2 (en) 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
HK1206612A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
JP5859399B2 (ja) * 2012-08-10 2016-02-10 太陽誘電株式会社 高周波回路および通信装置。
PT2895156T (pt) 2012-09-17 2019-06-28 Pfizer Processo para a preparação de nanopartículas terapêuticas
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
DK3019619T3 (da) 2013-07-11 2021-10-11 Modernatx Inc Sammensætninger, der omfatter syntetiske polynukleotider, som koder for crispr-beslægtede proteiner, og syntetiske sgrna'er, og anvendelsesfremgangsmåder
AU2014315287A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
DK3046584T3 (en) 2013-09-16 2017-10-02 Astrazeneca Ab THERAPEUTIC POLYMER NANOPARTICLES AND PROCEDURES FOR PREPARING AND USING THEREOF
KR102507624B1 (ko) 2013-11-22 2023-03-09 미나 테라퓨틱스 리미티드 C/ebp 알파 짧은 활성화 rna 조성물 및 사용 방법
SI3116547T1 (sl) 2014-03-14 2019-08-30 Pfizer, Inc. Terapevtski nanodelci, ki obsegajo terapevtsko stredstvo, in postopek izdelave ter uporabe le-teh
SG10201911695SA (en) 2014-05-14 2020-01-30 Targimmune Therapeutics Ag Improved polyethyleneimine polyethyleneglycol vectors
IL289934B2 (en) 2014-06-25 2023-04-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3169693B1 (en) 2014-07-16 2022-03-09 ModernaTX, Inc. Chimeric polynucleotides
EP3171895A1 (en) 2014-07-23 2017-05-31 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
CN114085198A (zh) 2015-06-29 2022-02-25 爱康泰生治疗公司 用于递送核酸的脂质和脂质纳米颗粒制剂
CA3002922A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
MA47016A (fr) 2015-10-22 2018-08-29 Modernatx Inc Vaccins contre les virus respiratoires
CA3003103A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Broad spectrum influenza virus vaccine
JP6925688B2 (ja) 2015-10-22 2021-08-25 モデルナティーエックス, インコーポレイテッド 水痘帯状疱疹ウイルス(vzv)のための核酸ワクチン
BR112018008090A2 (pt) 2015-10-22 2018-11-13 Modernatx Inc vacina de vírus do herpes simplex.
JP7687767B2 (ja) 2015-10-22 2025-06-03 モデルナティエックス インコーポレイテッド 呼吸器合胞体ウイルスワクチン
RS63986B1 (sr) 2015-10-28 2023-03-31 Acuitas Therapeutics Inc Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
LT3394093T (lt) 2015-12-23 2022-04-25 Modernatx, Inc. Ox40 ligandus koduojančių polinukleotidų naudojimo būdai
EP3400023A1 (en) 2016-01-10 2018-11-14 ModernaTX, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
US11485972B2 (en) 2017-05-18 2022-11-01 Modernatx, Inc. Modified messenger RNA comprising functional RNA elements
US11421011B2 (en) 2017-05-18 2022-08-23 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
EP3638292A1 (en) 2017-06-14 2020-04-22 ModernaTX, Inc. Polynucleotides encoding coagulation factor viii
EP4219715A3 (en) 2017-09-08 2023-09-06 MiNA Therapeutics Limited Stabilized cebpa sarna compositions and methods of use
EP4183882A1 (en) 2017-09-08 2023-05-24 MiNA Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
US11939601B2 (en) 2017-11-22 2024-03-26 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
WO2019104195A1 (en) 2017-11-22 2019-05-31 Modernatx, Inc. Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
JP7423522B2 (ja) 2017-11-22 2024-01-29 モダーナティエックス・インコーポレイテッド 尿素サイクル異常症の治療のためのオルニチントランスカルバミラーゼをコードするポリヌクレオチド
US11802146B2 (en) 2018-01-05 2023-10-31 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
EP3773745A1 (en) 2018-04-11 2021-02-17 ModernaTX, Inc. Messenger rna comprising functional rna elements
US11566246B2 (en) 2018-04-12 2023-01-31 Mina Therapeutics Limited SIRT1-saRNA compositions and methods of use
WO2019226650A1 (en) 2018-05-23 2019-11-28 Modernatx, Inc. Delivery of dna
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
MA53545A (fr) 2018-09-02 2021-07-14 Modernatx Inc Polynucléotides codant pour l'acyl-coa déshydrogénase à très longue chaîne pour le traitement de l'insuffisance en acyl-coa déshydrogénase à très longue chaîne
MX2021003015A (es) 2018-09-13 2021-07-15 Modernatx Inc Polinucleotidos que codifican glucosa-6-fosfatasa para el tratamiento de la glucogenosis.
EP3849594A2 (en) 2018-09-13 2021-07-21 Modernatx, Inc. Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease
AU2019339430A1 (en) 2018-09-14 2021-04-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide A1 for the treatment of Crigler-Najjar Syndrome
EP4613367A1 (en) 2018-09-21 2025-09-10 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes
MA53734A (fr) 2018-09-27 2021-08-04 Modernatx Inc Polynucléotides codant pour l'arginase 1 pour le traitement d'une déficience en arginase
WO2020097409A2 (en) 2018-11-08 2020-05-14 Modernatx, Inc. Use of mrna encoding ox40l to treat cancer in human patients
CA3125485A1 (en) 2019-01-11 2020-07-16 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
WO2020208361A1 (en) 2019-04-12 2020-10-15 Mina Therapeutics Limited Sirt1-sarna compositions and methods of use
JP2022532078A (ja) 2019-05-08 2022-07-13 アストラゼネカ アクチボラグ 皮膚及び創傷のための組成物並びにその使用の方法
US20220387628A1 (en) 2019-06-24 2022-12-08 Modernatx, Inc. Messenger rna comprising functional rna elements and uses thereof
MA56539A (fr) 2019-06-24 2022-04-27 Modernatx Inc Arn messager résistant à l'endonucléase et utilisations correspondantes
US20230235298A1 (en) 2020-06-01 2023-07-27 Modernatx, Inc. Phenylalanine hydroxylase variants and uses thereof
WO2021252354A1 (en) 2020-06-12 2021-12-16 University Of Rochester ENCODING AND EXPRESSION OF ACE-tRNAs
DK4182297T3 (da) 2020-07-16 2025-12-01 Acuitas Therapeutics Inc Kationiske lipider til brug i lipid-nanopartikler
JP2023544201A (ja) 2020-10-08 2023-10-20 ターグイミューン セラピューティクス アクチエンゲゼルシャフト がんを処置するための免疫療法
US20230406895A1 (en) 2020-11-13 2023-12-21 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
US20240226025A1 (en) 2021-03-24 2024-07-11 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
US20240189449A1 (en) 2021-03-24 2024-06-13 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
WO2022204371A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
US20240216288A1 (en) 2021-03-24 2024-07-04 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
JP2024511092A (ja) 2021-03-26 2024-03-12 ミナ セラピューティクス リミテッド TMEM173saRNA組成物及び使用方法
WO2022240806A1 (en) 2021-05-11 2022-11-17 Modernatx, Inc. Non-viral delivery of dna for prolonged polypeptide expression in vivo
WO2022266083A2 (en) 2021-06-15 2022-12-22 Modernatx, Inc. Engineered polynucleotides for cell-type or microenvironment-specific expression
US20240376445A1 (en) 2021-06-22 2024-11-14 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
US20250017867A1 (en) 2021-10-01 2025-01-16 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
CA3237153A1 (en) 2021-11-05 2023-05-11 Targimmune Therapeutics Ag Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
WO2023114943A2 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
AU2023215397A1 (en) 2022-02-07 2024-08-22 University Of Rochester Optimized sequences for enhanced trna expression or/and nonsense mutation suppression.
EP4482962A1 (en) 2022-02-24 2025-01-01 IO Biotech ApS Nucleotide delivery of cancer therapy
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
EP4499153A2 (en) 2022-03-25 2025-02-05 ModernaTX, Inc. Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
WO2023196399A1 (en) 2022-04-06 2023-10-12 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
MA71619A (fr) 2022-07-26 2025-05-30 Modernatx, Inc. Polynucléotides modifiés pour la régulation temporelle de l'expression
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
AU2023376546A1 (en) 2022-11-07 2025-05-15 Targimmune Therapeutics Ag Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
AU2023376540A1 (en) 2022-11-07 2025-05-15 Targimmune Therapeutics Ag Psma-targeting linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
IL320618A (en) 2022-11-07 2025-07-01 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted pairs containing polyethyleneimine and polyethylene glycol
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024130158A1 (en) 2022-12-16 2024-06-20 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
WO2024134199A1 (en) 2022-12-22 2024-06-27 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use
JP2026508256A (ja) 2023-02-23 2026-03-10 ユニバーシティー オブ ロチェスター 閉端dnaスレッド分子を作製するための薬剤及び方法
WO2024182301A2 (en) 2023-02-27 2024-09-06 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding galactose-1-phosphate uridylyltransferase (galt) for the treatment of galactosemia
WO2024197033A1 (en) 2023-03-21 2024-09-26 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of heart failure
WO2024206126A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
WO2024206329A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof
WO2024229321A1 (en) 2023-05-03 2024-11-07 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2025042806A2 (en) 2023-08-21 2025-02-27 Modernatx, Inc. C-met binding antibodies, nucleic acids encoding same, and methods of use
EP4520345A1 (en) 2023-09-06 2025-03-12 Myneo Nv Product
WO2025072482A1 (en) 2023-09-27 2025-04-03 Modernatx, Inc. Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof
WO2025101685A1 (en) 2023-11-09 2025-05-15 University Of Rochester Suppression of nonsense mutations using anticodon engineered (ace)-trnas
WO2025238236A1 (en) 2024-05-16 2025-11-20 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol
WO2025255199A1 (en) 2024-06-05 2025-12-11 Modernatx, Inc. Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof
WO2026006151A2 (en) 2024-06-24 2026-01-02 University Of Rochester Functionalization of ace-trna encoding synthetic linear picovectors
WO2026030209A1 (en) 2024-07-29 2026-02-05 University Of Rochester Use of decoding trnas to boost protein expression or function
WO2026027887A2 (en) 2024-08-02 2026-02-05 Mina Therapeutics Limited Hbg1/2-sarna compositions and methods of use
WO2026044055A1 (en) 2024-08-23 2026-02-26 Modernatx, Inc. Muc16 binding molecules, nucleic acids encoding same, and methods of use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6007845A (en) * 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
WO2002080846A2 (en) * 2001-04-03 2002-10-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
WO2004084871A1 (en) * 2003-03-26 2004-10-07 Ltt Bio-Pharma Co., Ltd. Intravenous nanoparticles for targenting drug delivery and sustained drug release
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
AU2004268377B2 (en) * 2003-09-02 2008-06-26 Novartis Ag Cancer treatment with epothilones
US8916206B2 (en) * 2005-12-26 2014-12-23 Ltt Bio-Pharma Co., Ltd. Nanoparticles containing water-soluble non-peptide low-molecular weight drug
US7842312B2 (en) * 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
CN1957911A (zh) * 2006-12-01 2007-05-09 济南康泉医药科技有限公司 一种抗实体肿瘤缓释剂
CN1961864A (zh) * 2006-12-12 2007-05-16 济南帅华医药科技有限公司 一种抗癌的组合物
CN1969816A (zh) * 2006-12-12 2007-05-30 济南帅华医药科技有限公司 一种含埃坡霉素的抗癌缓释剂
CN1969818A (zh) * 2006-12-12 2007-05-30 济南帅华医药科技有限公司 一种含埃坡霉素衍生物的抗癌缓释注射剂
CN101396340A (zh) * 2006-12-12 2009-04-01 济南帅华医药科技有限公司 一种含埃坡霉素衍生物的抗癌缓释注射剂
CN101433520A (zh) * 2006-12-12 2009-05-20 济南帅华医药科技有限公司 含埃坡霉素的抗癌缓释剂
CN101396342A (zh) * 2006-12-12 2009-04-01 济南帅华医药科技有限公司 含埃坡霉素衍生物的抗癌缓释注射剂
JP2010523595A (ja) * 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ(アミノ酸)ターゲッティング部分
JP5410434B2 (ja) * 2007-09-28 2014-02-05 バインド セラピューティックス インコーポレイテッド ナノ粒子を用いた癌細胞の標的化
DE102007059752A1 (de) * 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
ES2765240T3 (es) * 2008-06-16 2020-06-08 Pfizer Nanopartículas poliméricas cargadas de fármaco y procedimientos de fabricación y uso de las mismas
ES2776126T3 (es) * 2008-12-15 2020-07-29 Pfizer Nanopartículas de circulación prolongada para la liberación sostenida de agentes terapéuticos
EA201171195A8 (ru) * 2009-03-30 2014-08-29 Серулин Фарма Инк. Конъюгаты, частицы, композиции "полимер-агент" и способы их применения
CN102740895B (zh) * 2009-12-23 2016-02-24 伊利诺伊大学董事会 纳米轭合物以及纳米轭合物配制品

Similar Documents

Publication Publication Date Title
JP2013514381A5 (enExample)
JP2014138100A5 (enExample)
JP2014102408A5 (enExample)
JP2014501485A5 (enExample)
JP2011506530A5 (enExample)
JP2010219032A5 (enExample)
DK2651436T3 (da) Mycobakterie antigen sammensætning.
JP2013500200A5 (enExample)
JP2013525942A5 (enExample)
LT2616102T (lt) Provaistas, apimantis eksendino-linkerio konjugatą
DK3620175T3 (da) Højkoncentrerede antistofformuleringer
PL2630108T3 (pl) Sposób wytwarzania 2,3,3,3-tetrafluoropropenu
JP2014520090A5 (enExample)
JP2011170856A5 (enExample)
JP2013538128A5 (enExample)
EP2379475A4 (en) ISOMERIZATION OF 1,1,3,3-TETRAFLUORPROPES
BR112013016205A2 (pt) kit para cuidado oral.
JP2013540702A5 (enExample)
JP2014513003A5 (enExample)
HUE053623T2 (hu) Vegyületek és azok felhasználása
JP2013536184A5 (enExample)
JP2014500291A5 (enExample)
BR112013015986A2 (pt) composições para cuidados orais.
CL2011002525A1 (es) Uso de compuesto derivado de quinazolindiona para tratar una enfermedad cardiovascular.
JP2013531183A5 (enExample)